Recent Postings to generic-tadalafil.info

E-Alerts

Worst Pills, Best Pills Newsletter Articles

  View the entire November 2018 issue in PDF format

  View the entire October 2018 issue in PDF format

  • False-Hope Alzheimer’s Disease Drugs
    (October 2018)
    The FDA has approved four drugs for treating Alzheimer’s disease, a devastating brain disorder that affects nearly 6 million Americans, most of whom are elderly. Learn why we have designated each of these drugs as Do Not Use.
  • New Research Shows Drugs Associated with a Risk of Depression Are Widely Used
    (October 2018)
    In this article, we summarize the results of a recent research study showing that use of medications that have depression as a potential adverse effect is very common. We also identify some of the many prescription medications that can cause depression symptoms, including suicidal thoughts or behavior.
  • Review of Lamotrigine (LAMICTAL)
    (October 2018)
    For certain types of epilepsy, lamotrigine is an appropriate treatment for preventing seizures. Learn about the common and serious adverse effects that can occur while taking this drug and how to take this drug safely.
  • FDA Announces Recalls of Certain Valsartan-Containing Medications Because of Cancer-Causing Contaminant
    (October 2018)
    We have received numerous questions from readers asking what to do about the recent recalls of valsartan-containing drugs sold by certain companies that were found to be tainted with a probable carcinogen. In this article, we offer advice for those patients who have been taking valsartan.
  • Question & Answer
    (October 2018)
    Several readers have asked us whether the FDA’s recent approval of a drug that reverses the anticoagulant effect of apixaban (ELIQUIS) and rivaroxaban (XARELTO) alters our classification of these two drugs as Do Not Use. Read our answer.
  • HHS Inspector General Documents Big Pharma’s Price Gouging of Seniors
    (October 2018)
    In his editor’s column, Dr. Michael Carome discusses the implications of a recent government report which found that annual out-of-pocket expenses for brand-name drugs covered under Medicare Part D have skyrocketed in recent years.

  View the entire September 2018 issue in PDF format

Additional Information from Public Citizen

  • (November 1, 2018)
    Public Citizen sent a letter to the Federal Trade Commission (FTC) requesting an investigation of the use of falsified scientific citations in the advertisement and promotion of an illegal heart-toxic drug for treatment of cancer by Utopia Wellness, a Florida-based medical center. The medical’s website materials misleadingly claim that cesium chloride is safe and effective for treating cancer but offers no evidence from well-controlled clinical tests to support its claims.
  • (November 1, 2018)
    Public Citizen sent a letter to the Food and Drug Administration (FDA) requesting an investigation of the promotion and use of an illegal cesium chloride drug for treatment of cancer by Utopia Wellness, a Florida-based medical center. Under current FDA policies governing pharmacy compounding, no State-licensed pharmacy or licensed physician affiliated with Utopia Wellness currently may legally compound cesium chloride.
  • (November 1, 2018)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Anesthetic and Analgesic Drug Products Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject new drug application submitted by AcelRx Pharmaceuticals for sufentanil sublingual tablets because the drug is a dangerous, high potency opioid that does not provide any unique advantages over currently available opioids, but does pose unique risks.
  • (November 1, 2018)
    In a letter to the FDA, the chair of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee joined three Public Citizen experts in urging the agency to reject Acer Pharmaceuticals’ new drug application for sufentanil sublingual tablets for treatment of moderate-to-severe acute pain in a medically supervised setting. This opioid, which is five to 10 times more potent than fentanyl and 1,000 times more potent than morphine, would be abused and start killing people as soon as it hits the market.
  • (November 1, 2018)
    Public Citizen sent a letter to the Florida Board of Medicine requesting an investigation into the medical practice of Dr. Carlos Garcia, M.D., the Director of Medicine at Utopia Wellness. We specifically requested that the board investigate Dr. Garcia’s role in Utopia Wellness’s dissemination of false and misleading advertisements that promote the use of compounded intravenous cesium chloride as a treatment for cancer.